A bipartisan group of lawmakers will re-introduce a bill on Tuesday that would require drug makers to justify their pricing and provide a breakdown of their expenses before raising prices on some medicines.

Senate negotiators, meeting stiff resistance to the House’s plans to sharply reduce the scope and reach of Medicaid, are discussing a compromise that would maintain the program’s expansion under the Affordable Care Act but subject that larger version of Medicaid to new spending limits.

Kaiser Permanente raised $4.4 billion through a series of three bond offerings this month.

A proposal aiming to force pharmaceutical companies to disclose how they set insulin prices cleared its first hurdle at the Nevada Legislature on Wednesday, without a provision that sought a price cap on insulin.

The Trump administration has given states three extra years to carry out plans for helping elderly and disabled people receive Medicaid services without being forced to go into nursing homes.

The Congressional Budget Office is planning to release the week of May 22 an assessment of how the health-care legislation that the House just passed will impact federal spending.